Asymptomatic TB With Innovative Modified Short-course Regimens
Trial Parameters
Brief Summary
This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin.
Eligibility Criteria
Inclusion Criteria: * 1\. Age between 14 to 80 years; * 2\. Male or female; * 3\. Willing to provide signed informed consent, or parental consent and participant assent; * 4\. Individuals with respiratory tract specimen (including sputum/bronchoalveolar lavage fluid/lung tissue) positive for acid-fast bacilli smear/culture/molecular amplification for M. tuberculosis; * 5\. No unexplained TB-suggestive symptoms in the three months prior to screening, including cough lasting more than two weeks, night sweats, fever or weight loss; * 6\. If non-menopausal woman, agree to use or have used effective contraception during treatment. Exclusion Criteria: * 1\. Combined extrapulmonary tuberculosis; * 2\. Induviduals with extensive lesion (lesion involvement exceeding 50% or the aggregate diameter of all cavities exceeding 6 cm) ; * 3\. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of t